I found this other article that still confirms the effectiveness of Minocycline when used with Copaxone.
I have the feeling that Minocycline has the same effect taken alone as with Copax., which lets me think that CRABS companies are trying to save their royalties by proving a random need of taking them+ some more efficient new drugs.
(this can be quite dangerous as seen with Tysabri+ Avonex
Treatment With COPAXONE(R) Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients With Active Relapsing-Remitting Multiple Sclerosis 05 May 2007
New data from a randomised, double-blind study showed that a combination of COPAXONE® (glatiramer acetate injection) along with the oral antibiotic minocycline reduced T1 Gadolinium (Gd)-enhancing lesions of the brain by 63 percent (p=0.08 ) in patients with active relapsing-remitting multiple sclerosis (RRMS), as measured by magnetic resonance imaging (MRI), compared to those receiving COPAXONE® alone. Additionally, the nine-month study demonstrated that treatment with COPAXONE® in combination with minocycline reduced the number of new T2 lesions in patients by 65 percent (p=0.06). These results trended toward but did not reach statistical significance.
These data were presented at the 59th Annual Meeting of the American Academy of Neurology (AAN) in Boston, MA, April 28 -- May 5, 2007.
"The results of this study indicated that further exploration of this combination is warranted, as the established effect of COPAXONE® on disease activity may be boosted when used in combination with minocycline for the treatment of active relapsing-remitting patients," said Luanne Metz, M.D., professor at the Department of Clinical Neuroscience of the University of Calgary, and principal investigator. "In these patients, the combination was safe and well tolerated," she added.
Minocycline is a broad-spectrum antibiotic, which is used to treat pneumonia, acne, and infections of the skin, genital and urinary systems, and the central nervous system. In a small proof-of-concept trial of 10 RRMS patients, minocycline demonstrated an 84 percent relative reduction in mean total Gd-enhancing lesions and was well tolerated, and data published in the Journal of Neuroimmunology indicated that the combination of minocycline and COPAXONE® decreased neuron-inflammation, axonal loss and demyelination in an animal model of MS.
"COPAXONE® is one of the most frequently used RRMS therapies due to its proven efficacy and safety and unique presumed mechanism of action," said Metz. "In previous studies, COPAXONE® has shown efficacy and safety both in combination with intravenous steroids and after induction with the immunosuppressant mitoxantrone; its compatibility with other compounds may make it unique among the disease modifying class of drugs and a treatment of interest for the future study of combination therapies for MS," Metz added.
About the Study
This double-blind, randomised study evaluated the safety, tolerability and efficacy of the combination of COPAXONE® plus oral minocycline in the treatment of RRMS patients with active disease.
Patients in this study (n=44) with one or more T1-enhancing lesions on their screening MRI were randomised to receive either COPAXONE® 20 mg daily plus minocycline 100 mg twice daily or COPAXONE® plus placebo for nine months. Patients were assessed clinically and by MRI scans at screening and months 1, 3, 8 and 9. The primary outcome was the total number of T1-enhancing lesions at months 8 and 9.
Forty patients completed the study. Groups were balanced at baseline except for greater T1-enhancing lesion number in the COPAXONE® plus minocycline group (median 3 versus 2; mean 7.62 versus 2.43 (p=0.07)). Despite this imbalance, treatment trended toward significance in the COPAXONE® plus minocycline group. At months 8 and 9, the number of T1-enhancing lesions was reduced by 63 percent (mean 1.47 versus 2.95; p=0.08 ) and the number of new T2 lesions was reduced by 65 percent (mean 1.84 versus 5.14; p=0.06), compared to COPAXONE® alone. Relapse risk rate was also non-significantly reduced in the COPAXONE® plus minocycline group (0.19 versus 0.41; p=NS).
Source: Red Orbit © 2002-2007 redOrbit.com. All rights reserved (05/05/07)